Publications
Detailed Information
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, Jeongmin | - |
dc.contributor.author | Koh, Jiwon | - |
dc.contributor.author | Lee, Dae-Won | - |
dc.contributor.author | Kim, Jinyong | - |
dc.contributor.author | Ryu, Han Suk | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.date.accessioned | 2024-01-04T08:00:44Z | - |
dc.date.available | 2024-01-04T08:00:44Z | - |
dc.date.created | 2023-12-28 | - |
dc.date.created | 2023-12-28 | - |
dc.date.issued | 2023-12 | - |
dc.identifier.citation | Breast Cancer Research, Vol.25 No.1, p. 154 | - |
dc.identifier.issn | 1465-5411 | - |
dc.identifier.uri | https://hdl.handle.net/10371/198783 | - |
dc.description.abstract | Background: The role of HER2 amplification level in predicting the effectiveness of HER2-directed therapies has been established. However, its association with survival outcomes in advanced HER2-positive breast cancer treated with dual HER2-blockade remains unexplored. Methods: This is a single-center retrospective study of patients with advanced HER2-positive breast cancer treated with first-line pertuzumab, trastuzumab, and docetaxel. The primary objective was to ascertain the relationship between treatment outcomes and the level of HER2 amplification by in situ hybridization (ISH). Results: A total of 152 patients were included with a median follow-up duration of 50.0 months. Among the 78 patients who received ISH, a higher HER2/CEP17 ratio correlated significantly with longer PFS (HR 0.50, p = 0.022) and OS (HR 0.28, p = 0.014) when dichotomized by the median. A higher HER2 copy number also correlated significantly with better PFS (HR 0.35, p < 0.001) and OS (HR 0.27, p = 0.009). In multivariate analysis, the HER2/CEP17 ratio was an independent predictive factor for PFS (HR 0.66, p = 0.004) and potentially for OS (HR 0.64, p = 0.054), along with HER2 copy number (PFS HR 0.85, p = 0.004; OS HR 0.84, p = 0.049). Furthermore, the correlation between HER2 amplification level by ISH with PFS and OS was consistent across the HER2 IHC 1+/2+ and 3+ categories. Conclusions: This is the first study to report that a higher level of HER2 amplification by ISH is associated with improved PFS and OS in advanced HER2-positive breast cancer treated with dual HER2-blockade. Notably, HER2 amplification level had a predictive role regardless of IHC results. Even in patients with HER2 protein expression of 3+, treatment outcome to HER2-directed therapy was dependent on the level of HER2 gene amplification. | - |
dc.language | 영어 | - |
dc.publisher | BioMed Central | - |
dc.title | HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results | - |
dc.type | Article | - |
dc.identifier.doi | 10.1186/s13058-023-01746-w | - |
dc.citation.journaltitle | Breast Cancer Research | - |
dc.identifier.wosid | 001127023400003 | - |
dc.identifier.scopusid | 2-s2.0-85179703719 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 154 | - |
dc.citation.volume | 25 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Dae-Won | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GENE AMPLIFICATION | - |
dc.subject.keywordPlus | PLUS TRASTUZUMAB | - |
dc.subject.keywordPlus | HER2/CEP17 RATIO | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordAuthor | Dual HER2 blockade | - |
dc.subject.keywordAuthor | HER2 copy number | - |
dc.subject.keywordAuthor | HER2 in situ hybridization | - |
dc.subject.keywordAuthor | HER2 positive breast cancer | - |
dc.subject.keywordAuthor | HER2/CEP17 ratio | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.